PACS Group jumps as FY2026 outlook and bullish targets keep bid under shares
PACS Group shares rose after investors focused on the company’s strong FY2025 results and reiterated FY2026 outlook calling for $5.65B–$5.75B in revenue and $555M–$575M in adjusted EBITDA. The move also comes as recent analyst price targets (including $44 from UBS and $42 from Oppenheimer) imply upside from the current ~$34 level.
1. What’s moving the stock today
PACS Group (PACS) traded higher as investors continued to lean into the company’s latest fundamental update: robust FY2025 performance and a maintained FY2026 outlook. Management’s FY2026 guideposts call for revenue of $5.65 billion to $5.75 billion and adjusted EBITDA of $555 million to $575 million, reinforcing a growth-and-margin-expansion narrative that traders have been rewarding on up days.
2. The fundamentals bulls are keying on
PACS has positioned its story around scaling a large post-acute platform across multiple states, pairing acquisitions with operational improvement. The company has emphasized a strategy of expanding its footprint through a mix of leasing and real-estate acquisition, while also evaluating additional acquisition opportunities—elements that can support a growth premium when guidance remains intact.
3. Analyst framing and what to watch next
Sell-side targets published in recent weeks have stayed constructive, with examples including a $44 target from UBS (maintained Buy) and a $42 target from Oppenheimer (maintained Outperform), both dated March 4, 2026. The next major catalyst risk is the company’s next earnings update and any change to FY2026 guidance, alongside signals on acquisition pacing, reimbursement trends, and whether operating momentum stays strong enough to support upside revisions.